Lung Cancer in Black Patients

Black men have the highest lung cancer incidence and mortality rate of any group in the United States, including higher rates than white men despite smoking fewer cigarettes on average. The 2021 USPSTF guideline change was designed partly to address this: it doubled the number of Black Americans eligible for lung cancer screening by lowering the qualifying age to 50 and the pack-year threshold to 20. Most people who qualify still have not been screened. This page explains the disparity plainly, what drives it, and what you can do right now.

Early lung cancer usually causes nothing at all, which is exactly why screening exists. When symptoms do show up, they often look like everything else:

• A cough that does not go away after three weeks, or a long-standing smoker's cough that has changed in sound, depth, or frequency
• Coughing up blood or rust-colored sputum, even once
• Chest pain that is worse with deep breathing, coughing, or laughing
• Shortness of breath, wheezing, or new hoarseness
• Recurrent bronchitis or pneumonia in the same part of the lung
• Unexplained weight loss, loss of appetite, or fatigue that does not lift
• Bone pain (often back, hip, or shoulder), headaches, or new neurological symptoms, which can signal that disease has already spread
• Swelling in the face, neck, or arms (superior vena cava syndrome) or a drooping eyelid with a small pupil on one side (Pancoast tumor)

The screening test is annual low-dose CT (LDCT) of the chest. The original National Lung Screening Trial enrolled more than 53,000 heavy smokers and showed that LDCT cut lung cancer mortality by 15-20% compared to chest X-ray (NLST, New England Journal of Medicine, 2011). The trial enrolled people aged 55-74 with at least 30 pack-years of smoking, and that became the 2013 USPSTF eligibility window.

In March 2021, USPSTF updated the recommendation to a B grade for annual LDCT in adults aged 50 to 80 with at least 20 pack-years of smoking history who currently smoke or quit within the past 15 years. The age dropped five years, the pack-year threshold dropped by a third, and the Task Force was explicit about why: "Black persons who smoke have a higher risk of lung cancer than do White persons," with that risk gap most apparent at lower smoking intensity. Under the new criteria, screening eligibility increases by roughly 107% in non-Hispanic Black adults and 112% in Hispanic adults.

The expansion exists because the old criteria failed Black smokers. Aldrich's group showed that under the 2013 30-pack-year rule, only 32% of Black smokers who actually developed lung cancer would have been eligible for screening, compared with 56% of white smokers. The pack-year cutoff was excluding the very people at highest per-pack risk. The 2021 update narrows but does not close that gap, and some researchers (including the Vanderbilt team) argue for further race-conscious adjustment.

The catch in 2025: only about 17% of eligible Black adults are actually getting screened, per ACS. The recommendation is on the books. The uptake is not. If you qualify, ask. A pack a day for twenty years is twenty pack-years. Two packs a day for ten years is also twenty pack-years.

Treatment depends on cell type (NSCLC vs SCLC), stage (I-IV), and the molecular profile of the tumor.

Surgery. For early-stage NSCLC (typically stage I and II, sometimes IIIA), lobectomy by a thoracic surgeon offers the best chance of cure. Video-assisted thoracoscopic surgery (VATS) and robotic approaches have shortened recovery. Black patients have historically been less likely to receive surgical resection even when clinically eligible, a gap that is not explained by tumor characteristics or comorbidity alone, so confirm the recommendation against an NCCN-guideline-aware second opinion if surgery is on the table and being deferred.

Targeted therapy. Molecular testing on the biopsy specimen should look for EGFR, ALK, ROS1, BRAF, KRAS G12C, MET exon 14, RET, NTRK, HER2, and PD-L1 expression, at minimum. Each has at least one FDA-approved oral or infusion drug. Osimertinib for EGFR-mutant NSCLC, alectinib for ALK, sotorasib or adagrasib for KRAS G12C. If your pathology report does not list a broad-panel result, that is a question to ask before any first-line decision.

Immunotherapy. PD-1/PD-L1 checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab) are now first-line, alone or with chemotherapy, for most advanced NSCLC without a targetable driver mutation, and for limited and extensive SCLC. Response can be durable.

Chemotherapy and radiation. Platinum doublet chemotherapy (cisplatin or carboplatin with pemetrexed or paclitaxel) remains a backbone, often combined with immunotherapy. Stereotactic body radiation therapy (SBRT) is an option for early-stage tumors when surgery is not safe.

The trial gap. Black Americans are roughly 14% of the population and have historically been around 2-4% of enrollment in the pivotal lung cancer trials that defined the standards above. That underrepresentation means subgroup safety and efficacy data in Black patients is thin for most newer agents, and it is part of why drug labels carry a generic "insufficient data" line for some racial subgroups. Ask your oncologist whether there is an open trial at your treatment center or a nearby NCI-designated cancer center that you qualify for. Trial participation is treatment, not experimentation, when the trial drug is competing against the current standard.